Covid-19
AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints
Sipavibart demonstrated to offer a statistically significant decline in the symptomatic Covid-19 occurrence.
Sipavibart demonstrated to offer a statistically significant decline in the symptomatic Covid-19 occurrence.